ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 133 | +6 | 82.36M | $6.29B | +14 | −7 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | — |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | — |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | — |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | — |
| Q2 2024 | 9 | — | 6.44M | $167.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 2.94M | — | $76.37M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.94M | — | $76.37M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 1.59M | — | $41.20M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 948.44K | — | $24.65M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 948.44K | — | $24.65M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 529.25K | — | $13.76M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 188.31K | — | $4.89M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 100.00K | — | $2.60M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 73.90K | — | $1.92M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Wellington Management ✦ | 61.02K | — | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Wellington Management ✦ | 61.02K | — | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Wellington Management ✦ | 61.02K | — | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 61.02K | — | $1.59M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Fisher Asset Management ✦ | 11.74K | — | $305,226 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 7 holders, 11.03M shares, $23.90M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.00K sh · $173,920
Director · 11.60K sh · $1.01M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology